GSK commences succession plan for management of vaccines business
GlaxoSmithKline (GSK) announced management changes related to its vaccines business as part of a planned succession strategy. With immediate effect Jean Stephenne is appointed Chairman, GSK Biologicals. Mr Stephenne will assume this role in addition to his existing position as President, GSK Biologicals.
Over the next two years, operational responsibility for Biologicals will transition to Dr Moncef Slaoui. These new responsibilities will be in addition to those he currently holds as Chairman of Research & Development.
Andrew Witty, Chief Executive Officer, GlaxoSmithKline said: “Succession planning is fundamental to GSK’s long-term success and today’s changes are clear evidence that we are taking proactive steps to maintain excellent leadership in our business.
“Jean has built a world-leading vaccines business and as Chairman will continue to be instrumental in driving forward our public health agenda. Moncef has more than 17 years experience working in the vaccines area and has played a critical role in developing the strong pipeline we have today. These changes will ensure continued strong focus on delivery and development of this pipeline; they also reflect the more holistic approach we are taking to R&D capital investment.”
Other news from the department people
